New drug combo aims to outsmart kaposi sarcoma tumors

NCT ID NCT04303117

Recruiting now Disease control Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 21, 2026 · Updated 3 times

Summary

This study tests two drugs, PDS01ADC and M7824, that work with the immune system to fight Kaposi sarcoma (KS), a cancer often linked to HIV or organ transplants. The trial enrolls 80 adults with advanced KS that has not responded well to prior therapy. Participants receive PDS01ADC alone or with M7824 for up to 96 weeks. The goal is to see if these drugs are safe and can shrink tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: PDS01ADC (immune-boosting drug) and M7824 (drug that blocks cancer's defense mechanisms)
What this could lead to: If successful, this could offer a new treatment option for advanced Kaposi sarcoma that doesn't rely on standard chemotherapy.
What could go wrong: This is an early-phase trial (Phase I/II) with only 80 participants, so results may not apply to everyone. The drugs may cause side effects or fail to shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for KAPOSI SARCOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

AIDS Kaposi's sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

KAPOSI SARCOMA

Contacts and locations

Locations

National Institutes of Health Clinical Center
RECRUITING

Bethesda, Maryland, 20892, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.